NuVasive, Inc. (NASDAQ:NUVA) – Investment analysts at William Blair raised their Q4 2017 earnings estimates for NuVasive in a research report issued on Wednesday. William Blair analyst K. Krum now expects that the medical device company will earn $0.66 per share for the quarter, up from their prior forecast of $0.63. William Blair also issued estimates for NuVasive’s Q1 2018 earnings at $0.57 EPS and Q4 2018 earnings at $0.69 EPS.

A number of other research analysts have also recently commented on the company. Royal Bank Of Canada reaffirmed a “buy” rating and set a $75.00 target price on shares of NuVasive in a research report on Friday, September 8th. BTIG Research started coverage on NuVasive in a research report on Thursday, September 7th. They set a “buy” rating and a $82.00 target price for the company. Needham & Company LLC lowered NuVasive from a “hold” rating to an “underperform” rating in a research report on Monday, August 28th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $90.00 target price on shares of NuVasive in a research report on Wednesday, August 9th. Finally, Barclays PLC reaffirmed a “buy” rating and set a $80.00 target price on shares of NuVasive in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the company. NuVasive currently has a consensus rating of “Buy” and an average price target of $80.42.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/14/william-blair-weighs-in-on-nuvasive-inc-s-q4-2017-earnings-nuva.html.

Shares of NuVasive (NASDAQ:NUVA) opened at 58.44 on Thursday. NuVasive has a 52 week low of $56.70 and a 52 week high of $81.68. The firm has a market capitalization of $2.97 billion, a PE ratio of 92.03 and a beta of 1.08. The company’s 50 day moving average price is $64.95 and its 200-day moving average price is $72.64.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The firm had revenue of $260.60 million during the quarter, compared to the consensus estimate of $261.95 million. During the same quarter in the previous year, the company posted $0.40 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year.

In related news, CEO Gregory T. Lucier purchased 2,000 shares of the business’s stock in a transaction on Tuesday, August 29th. The stock was acquired at an average price of $61.52 per share, for a total transaction of $123,040.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Lesley H. Howe sold 3,970 shares of NuVasive stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $64.64, for a total value of $256,620.80. The disclosure for this sale can be found here. Insiders have acquired a total of 14,850 shares of company stock valued at $955,598 in the last quarter. Company insiders own 1.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of NUVA. Koch Industries Inc. lifted its position in shares of NuVasive by 26,406.7% during the 2nd quarter. Koch Industries Inc. now owns 982,337 shares of the medical device company’s stock worth $970,000 after buying an additional 978,631 shares in the last quarter. Voya Investment Management LLC lifted its position in shares of NuVasive by 43.7% during the 2nd quarter. Voya Investment Management LLC now owns 1,699,964 shares of the medical device company’s stock worth $130,761,000 after buying an additional 517,115 shares in the last quarter. OppenheimerFunds Inc. lifted its position in shares of NuVasive by 55.8% during the 1st quarter. OppenheimerFunds Inc. now owns 1,210,999 shares of the medical device company’s stock worth $90,438,000 after buying an additional 433,506 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of NuVasive by 118.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 546,740 shares of the medical device company’s stock worth $42,055,000 after buying an additional 296,715 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of NuVasive by 70.8% during the 1st quarter. Victory Capital Management Inc. now owns 715,321 shares of the medical device company’s stock worth $53,420,000 after buying an additional 296,568 shares in the last quarter.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.